Freya Biosciences Secures Major Funding to Revolutionize Women’s Reproductive Health

Securing Investments for Women’s Health Innovation

Freya Biosciences, under the leadership of CEO Colleen Acosta, has achieved a significant milestone by securing a substantial round of funding.

The investment, led by Sofinnova Partners and OMX Ventures and supported by a consortium including The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology, and Indaco Venture Partners, marks a crucial step in advancing women’s health innovations.

Clinical Advancements in Fertility Treatment

The primary focus of this funding will be the progression of Freya Biosciences’ lead drug candidate—an investigational vaginal microbial immunotherapeutic designed specifically for treating infertility in women facing dysbiotic vaginal microbiota.

Particularly targeting women undergoing assisted reproductive technology (ART), this pioneering drug candidate aims to address underlying reproductive health conditions that have limited viable treatment options.

Revolutionizing Women’s Health

Freya Biosciences, a clinical-stage biotech company headquartered in both Copenhagen, Denmark, and Boston, Massachusetts, is committed to transforming women’s health landscapes.

Under the visionary leadership of CEO Colleen Acosta, the company is dedicated to redefining fertility solutions for individuals who have been historically underserved in this realm.

By focusing on microbial immunotherapies, Freya Biosciences aims to address crucial immune factors impacting various reproductive health conditions, envisioning a future where optimal reproductive health is within everyone’s reach.